From intramuscular to nasal: unleashing the potential of nasal spray vaccines against coronavirus disease 2019

G Jin, R Wang, Y Jin, Y Song… - Clinical & Translational …, 2024 - Wiley Online Library
Coronavirus disease 2019, caused by severe acute respiratory syndrome coronavirus 2
(SARS‐CoV‐2), has affected 700 million people worldwide since its outbreak in 2019. The …

[HTML][HTML] COVID-19 Variants and Vaccine Development

Z Zhao, S Bashiri, ZM Ziora, I Toth, M Skwarczynski - Viruses, 2024 - mdpi.com
Coronavirus disease 2019 (COVID-19), the global pandemic caused by severe acute
respiratory syndrome 2 virus (SARS-CoV-2) infection, has caused millions of infections and …

[HTML][HTML] A Chymotrypsin-Dependent Live-Attenuated Influenza Vaccine Provides Protective Immunity against Homologous and Heterologous Viruses

P He, M Gui, T Chen, Y Zeng, C Chen, Z Lu, N Xia… - Vaccines, 2024 - mdpi.com
Influenza virus is one of the main pathogens causing respiratory diseases in humans.
Vaccines are the most effective ways to prevent viral diseases. However, the limited …

Intranasal influenza-vectored COVID-19 vaccines confer broad protection against SARS-CoV-2 XBB variants in hamsters

J Chen, C Chen, L Yuan, Y Chen, X Wang… - PNAS …, 2024 - academic.oup.com
Abstract The XBB. 1.5 subvariant has garnered significant attention due to its exceptional
immune evasion and transmissibility. Significantly, the evolutionary trajectory of SARS-CoV …

Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines

Y Wang, X Wei, Y Liu, S Li, W Pan, J Dai… - Frontiers in Cellular and …, 2024 - frontiersin.org
In the post-COVID-19 era, the co-circulation of respiratory viruses, including influenza, SARS-
CoV-2, and respiratory syncytial virus (RSV), continues to have significant health impacts …

[HTML][HTML] Influenza virus strains expressing SARS-CoV-2 receptor binding domain protein confer immunity in K18-hACE2 mice

NA Rader, KS Lee, AN Loes, OA Miller-Stump… - Vaccine: X, 2024 - Elsevier
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of
coronavirus disease (COVID-19), rapidly spread across the globe in 2019. With the …

Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice

H Yang, Y Xie, S Li, C Bao, J Wang, C Li… - Human Vaccines & …, 2024 - Taylor & Francis
Mucosal immunity plays a crucial role in combating and controlling the spread of highly
mutated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Recombinant …

SARS-CoV-2 and Influenza Co-Infection: Fair Competition or Sinister Combination?

T Narasaraju, VTK Chow, MD Pandareesh… - 2024 - preprints.org
The COVID-19 pandemic remains a serious public health problem globally. During winter flu
seasons, more aggressive SARS-CoV-2 infections with fatalities have been documented …

[PDF][PDF] ОПТИМИЗАЦИЯ ГРИППОЗНОГО ВЕКТОРА С МОДИФИЦИРОВАННЫМ БЕЛКОМ NS1 ДЛЯ ЭФФЕКТИВНОЙ ПРЕЗЕНТАЦИИ АНТИГЕНОВ …

АЮ ЕГОРОВ - new.influenza.spb.ru
4 ВВЕДЕНИЕ Актуальность темы исследования. Респираторно-синцитиальный вирус
(РСВ), наряду с вирусом гриппа и коронавирусом SARS-CoV-2, является одним из …